COLL vs SNY: fair value comparison
Collegium Pharmaceutical, Inc. and Sanofi · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, SNY currently sits closer to the top of our discount ranking. SNY carries the stronger quality grade.
| COLL | SNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $35.58 | $42.95 |
| 12-month range | $31.78–$47.11 | $41.63–$47.40 |
| Sector rank | #42 of 113 Healthcare | #41 of 113 Healthcare |
| Quality grade | C- | B |
| Leverage | High | Low |
| Margin trend | — | Expanding |
| Revenue growth | — | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: COLL fair value analysis · SNY fair value analysis